SEARCH:   Advanced

Blood, 1 November 2005, Vol. 106, No. 9, pp. 3314-3321. Prepublished online as a Blood First Edition Paper on July 14, 2005; DOI 10.1182/blood-2005-04-1377. This Article Full Text (PDF) All Versions of this Article: 2005-04-1377v1 106/9/3314    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Stelljes, M. Articles by Kienast, J. Search for Related Content PubMed PubMed Citation Articles by Stelljes, M. Articles by Kienast, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 4, 2005 Accepted June 30, 2005 Conditioning with 8 Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia Matthias Stelljes, Martin Bornhauser, Matthias Kroger, Joerg Beyer, Maria C Sauerland, Achim Heinecke, Bjorna Berning, Christian Scheffold, Gerda Silling, Thomas Buchner, Andreas Neubauer, Axel A Fauser, Gerhard Ehninger, Wolfgang E Berdel, and Joachim Kienast* Department of Medicine / Hematology and Oncology, University of Muenster, Muenster, Germany Department of Hematology/Oncology, University of Dresden, Dresden, Germany Department of Medicine, Hematology/Oncology, University of Marburg, Marburg, Germany Department of Medical Informatics and Biomathematics, University of Muenster, Muenster, Germany Clinic for BMT and Hematology/Oncology, Idar-Oberstein, Germany * Corresponding author; email: kienast{at}uni-muenster.de. Seventy-one patients with acute myeloid leukemia (AML), most of them (63/71) considered ineligible for conventional allogeneic hematopoietic stem cell transplantation (HSCT), were enrolled into a phase II study on reduced intensity myeloablative conditioning with fractionated 8 Gy total body irradiation (TBI) and fludarabine (120 mg/m2). Patients received mobilized peripheral blood stem cells (n=68) or bone marrow (n=3) from siblings (n=39) or unrelated donors (n=32). Thirty-six patients were transplanted in complete remission (CR) and 35 with untreated or refractory disease (non-CR). Median patient age was 51 years (range, 20-66). Sustained engraftment was attained in all evaluable patients. With a median follow-up of 25.9 months (range, 3.7-61.2) in surviving patients, probabilities of overall survival for patients transplanted in CR and non-CR were 81% and 21% at 2 years, respectively. Relapse-free survival rates were 78% and 16%. The cumulative incidence of non-relapse mortality (NRM) in CR patients was 8% at 2 years and beyond, but amounted to 37% at 2 years in non-CR patients. Outcome data in this poor risk population indicate that allogeneic HSCT from related or unrelated donors with 8 Gy TBI/fludarabine conditioning is feasible with low NRM and preserved antileukemic activity in AML patients in first or later CR. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020